Announcements after hours are never a good look.
In saying that with only 0.5 mill in sales last year the SP reaction will depend on how much blue sky was being priced in for this trial. Maybe the latest wee run up was in hope of a good announcement (hope not), or was it a reaction to the Norvartis withdrawal?
Down and then a bit of a bounce back is my best guess.
Ann: ELX LEAD Clinical trial results, page-11
-
- There are more pages in this discussion • 57 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EYE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
18.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $41.23M | |||
| Open | High | Low | Value | Volume |
| 19.0¢ | 19.0¢ | 18.0¢ | $24.11K | 132.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 137086 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.5¢ | 30000 | 1 |
View Market Depth
| Last trade - 14.41pm 04/10/2024 (20 minute delay) ? |
| EYE (ASX) Chart |